---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024988"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:45:53.787157+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Equillium Q3 net loss $13.7M ($0.40/shr); Metacrine deal to add $35M cash

## Summary
- Net loss $13.7M ($0.40/shr) vs $10.3M ($0.35) in Q3 2021; R&D $8.8M, G&A $4.5M.
- Cash, equivalents and investments $44.5M as of Sep 30; pending Metacrine acquisition expected to add ~$35M cash, extending runway into 2024.
- Positive interim itolizumab data in lupus nephritis: 83% achieved complete or partial response by week 28; 67% had >80% UPCR reduction.
- Initiated Phase 2 study of EQ101 in alopecia areata (30 subjects) and Phase 1 study of EQ102 in celiac disease; data expected in 2023.

## SEC filing metadata
- accession: 0000950170-22-024988
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017022024988/0000950170-22-024988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017022024988/eq-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024988
- JSON: https://secwatch.observer/filing/0000950170-22-024988.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024988.txt

## Key facts
- Earnings Releases
  Equillium, Inc. reported the third quarter ended September 30, 2022 results: net income $13.7 million, EPS $(0.40) per basic and diluted share.
  - Period: the third quarter ended September 30, 2022
  - Net income: $13.7 million
  - EPS: $(0.40) per basic and diluted share
  - Result: reported results
  source text: Net loss for the third quarter of 2022 was $13.7 million, or $(0.40) per basic and diluted share, compared with a net loss of $10.3 million, or $(0.35) per basic and diluted share for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746466/000095017022024988/0000950170-22-024988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.